Company Research Report: MSD Merck Sharp & Dohme AG
Company Overview
Name and Mission
- Name: MSD Merck Sharp & Dohme AG (known as MSD outside the USA and Canada)
- Mission: To lead in the field of research-driven biopharmaceuticals, focusing on scientific innovations that provide medicines and vaccines to improve global health.
Founding
- Year Founded: 1891
- Founder: George Merck, who established the company to distribute fine chemicals in New York City and adjacent regions.
Key People
- Notable Leadership: Dr. Corinna Lenz, Leader of MSD Schachen Site; Daria Tyuvina, HR Director MSD Switzerland.
- Business Units Heads: Joanna Keiller, Director Business Unit Primary Care & Vaccines; Angela Weber, Director Business Unit Pharma.
Headquarters
- Location: Werftestrasse 4, CH-6005 Luzern, Switzerland
Employees
- Number of Employees: Global footprint with over 21,800 involved in research and development; over 490 employees at the Schachen site alone.
Revenue
- Annual Investment in R&D: USD 30.5 billion in 2023 specific revenue figures are not mentioned.
Recognition
- Known for being a Top Employer, achieving this status for the 13th consecutive year, and having an inclusive and diverse workplace culture.
Areas of Specialization
- Focus on oncology, vaccines, infectious diseases, and diabetes treatment.
Products
Categories of Products
- Medications: Includes key products like BRIDION, CANCIDAS, DELSTRIGO, JANUMET, JANUVIA, KEYTRUDA, among others.
- Vaccines: ERVEBO, GARDASIL 9, HBVAXPRO, M-M-RVAXPRO, among others.
High-Level Descriptions and Key Features
- Medications: Focus primarily on oncology, infectious diseases, and diabetes, implementing therapies such as immunotherapy, SGLT-2 inhibitors, and antiretroviral drugs.
- Vaccines: Innovative vaccines designed for prevention of diseases such as HPV, Ebola, measles, mumps, etc.
Recent Developments
Key Developments
- New Approvals: Recent Swissmedic approvals include Pembrolizumab combinations for urothelial carcinoma and pulmonary arterial hypertension treatments.
- Milestones: MSD's Schachen site in Lucerne focuses on biotechnological innovations, manufacturing for global clinical trials, and forensic analysis of product authenticity.
- Commitment to Transparency & Responsibility: Open disclosure of financial engagements, participation in public health initiatives, and local social responsibility projects.
New Products and Features
- Sotatercept Approval: For treatment of pulmonary arterial hypertension in WHO functional class II-III adults.
- Pembrolizumab Enhancements: Expanding use in combination therapies for various cancer treatments.
Partnerships and Alliances
- HPV Alliance Switzerland: MSD is a part of this collaboration aiming to prevent and eliminate HPV-associated conditions.
- allianz q & Allianz Gesundheitskompetenz: Collaborates on initiatives for improved healthcare quality and competence in Switzerland.
Additional Information
- MSD conducts wide-ranging clinical trials, with 48 active studies in Switzerland addressing various health challenges, structured through a robust pipeline.
- Engaged in global initiatives such as MSD for Mothers, aiming to reduce maternal mortality, and the Mectizan Donation Program combatting river blindness.
- The company maintains a transparent disclosure policy in accordance with EFPIA standards, demonstrating its commitment to ethical business practices.
Social and Corporate Responsibility
- Provides extensive community support, particularly focused on reducing food waste and sponsoring health-related events such as cancer charity events.
- Active in corporate volunteering, allowing employees 40 hours of voluntary service annually to contribute to social causes.
This report highlights MSD's commitment to advancing healthcare through innovation, partnerships, and ethical responsibility. Their ongoing developments and recognitions further establish their position as a leader in the biopharmaceutical industry.
